Monoclonal Anti-CD82 antibody produced in mouse

The cluster of differentiation 82 (CD82)/Kangai 1 (KAI1), a type III transmembrane protein, is a member of the tetraspanin superfamily. It has four putative transmembrane domains and one small and one large extracellular loop. CD82 is widely expressed in normal tissues. Its mRNA is seen at high levels in the spleen, placenta, lung, liver, kidney, and prostate. CD82 was previously identified as lymphocyte cell-surface protein. The KAI1/CD82 gene is mapped to human chromosome 11p11.2.

C91/PL (human HTLV-1+ T cell line)

The cluster of differentiation 82 (CD82)/Kangai 1 (KAI1) protein is a metastasis suppressor. It inhibits the migration and invasion of cancer cells. CD82 plays a key role in cell adhesion, fusion, apoptosis, and morphogenesis. CD82 can mobilize intracellular Ca²⁺ in lymphocytes. It acts as an accessory molecule in the activation of the T-cell. CD82 has an inhibitory role in syncytium formation caused by the human T-cell leukemia virus in immune cells (HTLV). Lower expression of CD82 is observed in several cancers, including prostate and lung cancer.

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Solution in phosphate buffered saline, pH 7.4, with 15 mM sodium azide.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.